IVEMEND

This brand name is authorized in Austria, Canada, Croatia, Estonia, Finland, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, South Africa, Spain, UK.

Active ingredients

The drug IVEMEND contains one active pharmaceutical ingredient (API):

1	Fosaprepitant UNII D35FM8T64X - FOSAPREPITANT DIMEGLUMINE
	Fosaprepitant is the prodrug of aprepitant and when administered intravenously is converted rapidly to aprepitant. The contribution of fosaprepitant to the overall antiemetic effect has not fully been characterised, but a transient contribution during the initial phase cannot be ruled out.
	Read more about Fosaprepitant

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
IVEMEND Powder for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A04AD12	Aprepitant	A Alimentary tract and metabolism → A04 Antiemetics and antinauseants → A04A Antiemetics and antinauseants → A04AD Other antiemetics
Discover more medicines within A04AD12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1491397, 1491409
ES	Centro de información online de medicamentos de la AEMPS	07437003
FI	Lääkealan turvallisuus- ja kehittämiskeskus	095813
GB	Medicines & Healthcare Products Regulatory Agency	184714
IT	Agenzia del Farmaco	041018019, 041018021, 041018033, 041018045
LT	Valstybinė vaistų kontrolės tarnyba	1056405, 1056406
NL	Z-Index G-Standaard	15638227
NL	Z-Index G-Standaard, PRK	95230
PL	Rejestru Produktów Leczniczych	100239838
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W52761001, W52761002
ZA	Health Products Regulatory Authority	43/5.7.2/0001, 45/5.7.2/0871